Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Caux

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
The British Journal of Dermatology|May 7, 2020
Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scoresL Ferries, A Gillibert, S Duvert-Lehembre, et al.
American Journal of Human Genetics|October 9, 2001
Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndromeC Lefèvre, F Jobard, F Caux, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 28, 2023
Lobular panniculitis and diffuse osteonecrosis occurring during anti-MEK and anti-BRAF combination therapy for metastatic melanomaS Tzoumpa, B Villette, A C Tieng, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|September 26, 2015
Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013E Sbidian, C Hotz, J Seneschal, et al.
The British Journal of Dermatology|December 21, 2016
Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adultsJ Gottlieb, S Ingen-Housz-Oro, M Alexandre, et al.
The British Journal of Dermatology|November 23, 2017
International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisitaC Prost-Squarcioni, F Caux, E Schmidt, et al.
The British Journal of Dermatology|June 26, 2021
International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg<sup>-1</sup> per day starting dose of oral corticosteroids to treat bullous pemphigoidV Hébert, S Bastos, K Drenovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2023
A retrospective study on the liver toxicity of oral retinoids in Chanarin-Dorfman syndromeC Valette, N Jonca, J Fischer, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
The British Journal of Dermatology|May 7, 2020
Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scoresL Ferries, A Gillibert, S Duvert-Lehembre, et al.
American Journal of Human Genetics|October 9, 2001
Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndromeC Lefèvre, F Jobard, F Caux, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 28, 2023
Lobular panniculitis and diffuse osteonecrosis occurring during anti-MEK and anti-BRAF combination therapy for metastatic melanomaS Tzoumpa, B Villette, A C Tieng, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|September 26, 2015
Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013E Sbidian, C Hotz, J Seneschal, et al.
The British Journal of Dermatology|December 21, 2016
Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adultsJ Gottlieb, S Ingen-Housz-Oro, M Alexandre, et al.
The British Journal of Dermatology|November 23, 2017
International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisitaC Prost-Squarcioni, F Caux, E Schmidt, et al.
The British Journal of Dermatology|June 26, 2021
International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg<sup>-1</sup> per day starting dose of oral corticosteroids to treat bullous pemphigoidV Hébert, S Bastos, K Drenovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2023
A retrospective study on the liver toxicity of oral retinoids in Chanarin-Dorfman syndromeC Valette, N Jonca, J Fischer, et al.
Pageof 7